References
- T. Inoue, K. Croce, T. Morooka, M. Sakuma, K. and D. I. Simon, "Vascular Inflammation and Repair," JACC., 4, 1057-1066 (2011).
- G. Niccoli and R. A. Montone, "The Evolving Role of Inflammatory Biomarkers in Risk Assessment After Stent Implantation," JACC., 56, 1783-1793 (2010). https://doi.org/10.1016/j.jacc.2010.06.045
- C. Stettler, S. Wandel, S. Allemann, et al., "Outcomes associated with drug-eluting and bare-metal stents: a collaborative network metaanalysis," Lancet, 370, 937-948 (2007). https://doi.org/10.1016/S0140-6736(07)61444-5
- R. G. Agustina, R. Bibiana, R. G. Gaston, and E. R. Alfredo, "Advantages and disadvantages of biodegradable platforms in drug eluting stents," WJC, 3, 84-92 (2011). https://doi.org/10.4330/wjc.v3.i3.84
- Y. Goueffic, S. Potter-Perigo, and C. K. Chan, "Sirolimus blocks the accumulation of hyaluronan (HA) by arterial smooth muscle cells and reduces monocyte adhesion to the ECM," Atherosclerosis, 195, 23-30 (2007). https://doi.org/10.1016/j.atherosclerosis.2006.11.023
- M. Hilker, M. Buerke, and M. Guckenbiehl, "Rapamycin reduces neointima formation during vascular injury," VASA, 32, 10-13 (2003). https://doi.org/10.1024/0301-1526.32.1.10
- J. Park, H. Ha, H. J. Ahn et al., "Sirolimus inhibits platelet-derived growth factor-induced collagen synthesis in rat vascular smooth muscle cells," Transplant Proc., 37, 3459-3462 (2005). https://doi.org/10.1016/j.transproceed.2005.09.066
- R. Wessely, A. Kastrati, and A. Schomig, "Late restenosis in patients receiving a polymer-coated sirolimus-eluting stent," Ann. Intern. Med., 143, 392-394 (2005). https://doi.org/10.7326/0003-4819-143-5-200509060-00119
- R. Virmani, F. Liistro, G. Stankovic, et al., "Mechanism of late instent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans," Circulation, 106, 2649-2651 (2002). https://doi.org/10.1161/01.CIR.0000041632.02514.14
- J. E. Sousa, M. A. Costa, A. C. Abizaid, B. J. Rensing, et al., "Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound followup," Circulation, 104, 2007-2011 (2001). https://doi.org/10.1161/hc4201.098056
- M. C. Morice, P. W. Serruys, J. E Sousa, J. Fajadet, E. B. Hayashi, M. Perin, et al., "A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization," N. Eng. J. Med. 346, 1773-1780 (2002). https://doi.org/10.1056/NEJMoa012843
- J. W. Moses, M. B. Leon, J. J Popma, P. J Fitzgerald, D. R. Holmes, et al., "Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery," N. Engl. J Med., 349, 1315-1323 (2003). https://doi.org/10.1056/NEJMoa035071
- E. Grube, S. Silber, K. E Hauptmann, R. Mueller, L. Buellesfeld, U. Gerckens, and M. E. Russell, "TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slowrelease paclitaxel-eluting stent for de novo coronary lesions," Circulation, 107, 38-42 (2003). https://doi.org/10.1161/01.CIR.0000047700.58683.A1
- A. Colombo, J. Drzewiecki, A. Banning, E. Grube, K. Hauptmann, S. Silber, D. Dudek, S. Fort, F. Schiele, K. Zmudka, G. Guagliumi, and M. E. Russell, "Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel eluting stents for coronary artery lesions," Circulation, 108, 788-794 (2003). https://doi.org/10.1161/01.CIR.0000086926.62288.A6